HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) --

德克萨斯州休斯顿，2025年4月2日（环球新闻社）--

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW)

Nexalin科技公司（纳斯达克：NXL；NXLIW）

(the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA).

（“公司”或“Nexalin”）是大脑深层颅内频率刺激（DIFS™）领域的领导者，今天宣布已成功在加州大学圣地亚哥分校（UCSD）与其合作的圣地亚哥退伍军人医疗系统（San Diego VA）进行的临床试验中招募到首批患者。

The company began treatment of the first patients this week with the Nexalin HALO™..

本周，该公司开始使用Nexalin HALO™治疗首批患者。

This significant milestone marks the transition from patient recruitment to active participation in the study, which aims to evaluate Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, delivered through its HALO™ Clarity devices, as a potential treatment for mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military personnel and the civilian population.

这一重要里程碑标志着从患者招募到积极参与研究的过渡，该研究旨在评估Nexalin公司通过其HALO™ Clarity设备提供的专有深层颅内频率刺激（DIFS™）技术，作为治疗军人和平民轻度创伤性脑损伤（mTBI）和创伤后应激障碍（PTSD）的潜在疗法。

The collaboration with UCSD and the San Diego VA underscores Nexalin’s commitment to advancing breakthrough treatment options for patients who are underserved by current therapies..

与加州大学圣地亚哥分校和圣地亚哥退伍军人事务部的合作，彰显了Nexalin为那些目前治疗方法未能满足需求的患者推进突破性治疗选择的承诺。

Mark White, CEO of Nexalin Technology, commented, “We are thrilled to announce that the first patients have now been successfully enrolled and treatment has begun in this important clinical trial at UCSD with the new Nexalin HALO™ headset. This marks a pivotal step forward as we move toward initiating treatments to civilians and veterans struggling with TBI and PTSD.

Nexalin Technology首席执行官马克·怀特评论道：“我们非常高兴地宣布，首批患者现已成功入组，并在加州大学圣地亚哥分校（UCSD）使用全新的Nexalin HALO™耳机开始了这一重要临床试验的治疗。这标志着我们在为遭受创伤性脑损伤（TBI）和创伤后应激障碍（PTSD）的平民和退伍军人提供治疗的道路上迈出了关键一步。”

We believe this study will provide critical insights into the efficacy and safety of our innovative DIFS™ technology, helping us further validate its potential as a transformative, drug-free approach to treating mental health disorders.”.

我们相信，这项研究将为我们创新的DIFS™技术的有效性和安全性提供重要的见解，帮助我们进一步验证其作为一种变革性的、非药物治疗心理健康障碍方法的潜力。"

The study is designed to gather comprehensive data on the impact of Nexalin’s DIFS™ technology in treating mental health conditions, particularly for veterans and other patient populations who often face limited treatment options. The results from this clinical trial will contribute to Nexalin’s broader regulatory and commercialization strategy as the Company works toward gaining further approvals and expanding the reach of its technology..

这项研究旨在收集关于Nexalin的DIFS™技术在治疗心理健康状况（尤其是常面临有限治疗选择的退伍军人和其他患者群体）方面的全面数据。该临床试验的结果将有助于Nexalin更广泛的监管和商业化战略，因为公司正致力于获得进一步批准并扩大其技术的覆盖范围。

“We are pleased to work alongside esteemed researchers at UCSD in collaboration with the San Diego VA as we advance this study,” White continued. “Our goal is to offer new hope to individuals struggling with PTSD, depression, and anxiety, and we look forward to analyzing the findings as the trial progresses.”.

“我们很高兴能与加州大学圣地亚哥分校的知名研究人员以及圣地亚哥退伍军人事务部合作推进这项研究，”怀特继续说道。“我们的目标是为那些与创伤后应激障碍、抑郁和焦虑作斗争的人们带来新的希望，我们期待在试验进行过程中分析研究结果。”

The trial follows the recent successful shipment and integration of Nexalin’s HALO™ Clarity devices at UCSD, where they are being used to provide non-invasive, at-home neurostimulation therapy with AI-integrated remote monitoring. Nexalin’s Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS) enable real-time tracking of patient adherence and treatment progress.

该试验是在加州大学圣地亚哥分校（UCSD）近期成功交付并整合Nexalin的HALO™ Clarity设备后进行的，这些设备正被用于提供非侵入式、在家使用的神经刺激治疗，并结合人工智能远程监控。Nexalin的电子数据采集（EDC）平台和患者监测系统（PMS）能够实时跟踪患者的依从性和治疗进展。

As the study progresses, additional HALO™ Clarity devices will be deployed to ensure optimal patient coverage and data collection..

随着研究的进展，将部署更多的HALO™ Clarity设备，以确保最佳的患者覆盖和数据收集。

About Nexalin Technology, Inc.

关于Nexalin科技公司

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues.

Nexalin设计和开发创新的神经刺激产品，以独特的方式帮助应对全球持续蔓延的心理健康问题。Nexalin的所有产品均为非侵入式，对人体无感知，旨在为心理健康问题患者提供缓解。Nexalin利用生物电子医学技术来治疗心理健康问题。

Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects.

Nexalin认为其神经刺激医疗设备可以穿透与精神健康障碍相关的大脑中部深层结构。Nexalin认为其下一代设备中穿透更深的波形将产生增强的患者反应，且没有任何不良副作用。

The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: .

Nexalin Gen-2 15毫安神经刺激装置已在中国、巴西和阿曼获得批准。有关该公司的更多信息，请访问：。

https://nexalin.com/

https://nexalin.com/

.

。

About

关于

HALO™ Clarity

HALO™ Clarity

The HALO™ Clarity device currently is under evaluation, and to date, is not approved for marketing and commercial sale in the U.S. The safety and efficacy of the HALO™ Clarity device have not been fully evaluated by the FDA. For more information about the HALO Clarity device, visit

HALO™ Clarity 设备目前正处于评估阶段，迄今为止，尚未获得在美国市场销售的批准。HALO™ Clarity 设备的安全性和有效性尚未得到 FDA 的全面评估。如需更多关于 HALO Clarity 设备的信息，请访问

www.nexalin-usa.com

www.nexalin-usa.com

.

。

Forward-looking statements

前瞻性声明

This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024, and other filings as filed with the Securities and Exchange Commission.

本新闻稿包含构成“前瞻性声明”的陈述。这些声明涉及未来事件或Nexalin未来的财务表现。任何涉及对未来事件或情况的预期、预测或其他描述的声明，或不是基于历史事实的声明（包括但不限于声明Nexalin或其管理层“认为”、“预期”、“预计”、“计划”、“意图”以及类似表述），均应被视为涉及风险和不确定性的前瞻性声明，可能导致实际事件或Nexalin的实际结果与前瞻性声明中所示的内容存在重大差异。前瞻性声明受制于许多条件，其中许多条件超出公司的控制范围，包括公司截至2024年12月31日年度的Form 10-K报告中“风险因素”部分所列内容以及其他向证券交易委员会提交的文件。

Copies of such filings are available on the SEC’s website, .

此类文件的副本可在SEC的网站上获取，。

www.sec.gov

www.sec.gov

. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

此类前瞻性声明是截至本文件发布之日作出的，随着时间的推移可能会过时。此类前瞻性声明是截至本文件发布之日作出的，随着时间的推移可能会过时。公司没有义务更新这些声明以反映本发布日期之后的修订或变化，除非法律要求。

.

。

Contact:

联系：

Crescendo Communications, LLC

增长通讯有限责任公司

Tel: (212) 671-1020

电话：（212）671-1020

Email:

电子邮件：

NXL@crescendo-ir.com

NXL@crescendo-ir.com